

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit, Room 2E04

2900 Crystal Drive
Arlington, VA 22202-3514

Telephone: (703) 308-2733
APR 10 2007

In re Application of

Application Number

07/1746,020

Filed

Aug, 15, 1991

Paper No. 720

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 5541334, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

M. Shahab

Signature

SHAHAB G. HAVOOR

Typed or printed name

Registration Number, if applicable

(703) 553-0000

Telephone Number

~~RECEIVED~~
Date

FOR PTC USE ONLY

Approved by: File Information Unit
(initials)

Unit: _____

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US005541334A

United States Patent [19]
Kempf et al.

[11] **Patent Number:** **5,541,334**
[45] **Date of Patent:** **Jul. 30, 1996**

[54] **RETROVIRAL PROTEASE INHIBITING COMPOUNDS**

[75] Inventors: **Dale J. Kempf, Libertyville; Daniel W. Norbeck, Lindenhurst; Lynn M. Codacovi, Antioch, all of Ill.**

[73] Assignee: **Abbott Laboratories, Abbott Park, Ill.**

[21] Appl. No.: **409,380**

[22] Filed: **Mar. 23, 1995**

Related U.S. Application Data

[62] Division of Ser. No. 270,210, Aug. 23, 1994, which is a division of Ser. No. 121,673, Sep. 14, 1993, Pat. No. 5,354,866, which is a continuation of Ser. No. 777,626, Oct. 23, 1991, abandoned, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, abandoned, which is a continuation-in-part of Ser. No. 516,170, Nov. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Pat. No. 5,142,056, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned.

[51] Int. Cl. ⁶ **C07D 277/30**

[52] U.S. Cl. **548/204**

[58] Field of Search **548/204**

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,142,056 8/1992 Kempf et al. 546/265

5,354,866 10/1994 Kempf et al. 546/265

FOREIGN PATENT DOCUMENTS

393445	10/1990	European Pat. Off.
402646	12/1990	European Pat. Off.
428849	5/1991	European Pat. Off.
441192	8/1991	European Pat. Off.
486948	5/1992	European Pat. Off.
3829594	3/1990	Germany
4003575	8/1992	Germany
WO88/02374	4/1988	WIPO
WO92/00948	8/1990	WIPO
WO90/09191	8/1990	WIPO
WO91/18866	12/1991	WIPO
WO92/06996	4/1992	WIPO
WO92/20665	11/1992	WIPO
WO93/01174	1/1993	WIPO

Primary Examiner—Jane Fan
Attorney, Agent, or Firm—Steven R. Crowley

[57] **ABSTRACT**

A retroviral protease inhibiting compound of the formula A—X—B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.

2 Claims, No Drawings